Literature DB >> 31463718

Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo.

Wei Zhao1, Juan Li2, Ping Li2, Fei Guo1, Pengfei Gao1, Junjie Zhang1, Zechen Yan3, Lei Wang1, Da Zhang1, Pan Qin1, Guoqiang Zhao4, Jiaxiang Wang5.   

Abstract

BACKGROUND: Our previous study identified a Wilms tumor-suppressing peptide (WTSP) that was upregulated in healthy children, but downregulated in children with Wilms tumor (WT). This study aimed to investigate the effect of WTSP on WT growth in vivo and in vitro.
METHODS: WTSP was synthesized by solid-phase synthesis of FOMC-protected amino acids. Cell growth curve, cytotoxicity, and apoptosis of WTSP-treated human WT cell line (SK-NEP-1) were determined by cell count, Cell Counting Kit-8 assay, and flow cytometry. The expression of key proteins of four WT-associated signaling pathways was determined by real-time PCR and western blotting. The WT xenograft mouse model was established by the armpit injection of SK-NEP-1 cells. The TUNEL assay was used to detect apoptosis in mouse tumor cells.
RESULTS: WTSP inhibited the proliferation of SK-NEP-1 cells in a dose- and time-dependent manner, and it arrested SK-NEP-1 cells in G2/M phase. WTSP-treated cells exhibited a low expression of PCNA and Bcl-2 and high expression of Bax. The expression of β-catenin was markedly changed after WTSP treatment. WTSP-treated mice had significantly smaller tumors than untreated mice.
CONCLUSION: Our findings indicated an anti-tumor effect of WTSP, which is correlated with Wnt/β-catenin pathway. This newly identified peptide may exert a therapeutic effect of WT in the future.

Entities:  

Keywords:  Tumor-suppressing peptide; Wilms tumor; m/z 6455.5 Da; β-Catenin

Mesh:

Substances:

Year:  2019        PMID: 31463718     DOI: 10.1007/s00432-019-03003-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

Review 1.  Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion.

Authors:  B Antonsson
Journal:  Cell Tissue Res       Date:  2001-10-30       Impact factor: 5.249

Review 2.  Pediatric malignancies: neuroblastoma, Wilm's tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma.

Authors:  Katherine P Davenport; Felix C Blanco; Anthony D Sandler
Journal:  Surg Clin North Am       Date:  2012-04-26       Impact factor: 2.741

3.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

Review 4.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids.

Authors:  Gregory Gregoriadis; Sanjay Jain; Ioannis Papaioannou; Peter Laing
Journal:  Int J Pharm       Date:  2005-08-26       Impact factor: 5.875

Review 5.  The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis.

Authors:  Marla Karine Amarante; Carlos Eduardo Coral de Oliveira; Carolina Batista Ariza; Alberto Yoichi Sakaguchi; Cintya Mayumi Ishibashi; Maria Angelica Ehara Watanabe
Journal:  Int Rev Immunol       Date:  2017-05-08       Impact factor: 5.311

6.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 7.  Wilms tumor.

Authors:  Andrew M Davidoff
Journal:  Adv Pediatr       Date:  2012

8.  Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.

Authors:  D M Green; Y A Grigoriev; B Nan; J R Takashima; P A Norkool; G J D'Angio; N E Breslow
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

Review 9.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

10.  Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Authors:  Samantha Gadd; Vicki Huff; Chiang-Ching Huang; E Cristy Ruteshouser; Jeffrey S Dome; Paul E Grundy; Norman Breslow; Lawrence Jennings; Daniel M Green; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

View more
  2 in total

1.  FOXO3a inhibits nephroblastoma cell proliferation, migration and invasion, and induces apoptosis through downregulating the Wnt/β‑catenin signaling pathway.

Authors:  Cheng Qian; Qiang Liu
Journal:  Mol Med Rep       Date:  2021-09-13       Impact factor: 2.952

2.  Lysosomal dysfunction and autophagy blockade contribute to autophagy-related cancer suppressing peptide-induced cytotoxic death of cervical cancer cells through the AMPK/mTOR pathway.

Authors:  Yang Yang; Qi Wang; Dongjian Song; Ruirui Zen; Lei Zhang; Yingjun Wang; Heying Yang; Da Zhang; Jia Jia; Jiao Zhang; Jiaxiang Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.